# Cancer Pharmacology Basics

**Notes on Targeted Therapies, Immunotherapies, and Kinase Inhibitors**

---

## Key Concepts
- **Targeted Therapy**: Drugs targeting specific genetic mutations or pathways in cancer cells.
- **Immunotherapy**: Agents that modulate the immune system to attack tumors.
- **IC50**: Drug concentration needed to inhibit 50% of target activity (lower = more potent).
- **FDA-Approved**: Standard-of-care treatments with robust clinical evidence.
- **Investigational**: Drugs in clinical trials (not yet approved).

---

## Drug Classes & Examples

### 1. **EGFR Inhibitors**
- **Mechanism**: Block EGFR signaling in tumors with activating mutations.
- **Examples**:
  - *Osimertinib*: Targets T790M mutation in NSCLC (IC50: 0.15 nM).
  - *Erlotinib*: For EGFR L858R/exon 19 del (IC50: 0.019 nM).

### 2. **ALK/ROS1 Inhibitors**
- **Mechanism**: Inhibit ALK/ROS1 fusion proteins.
- **Examples**:
  - *Crizotinib*: First-gen ALK/ROS1/MET inhibitor (IC50: 0.3 nM).
  - *Lorlatinib*: 3rd-gen, crosses blood-brain barrier (IC50: 0.02 nM).

### 3. **PARP Inhibitors**
- **Mechanism**: Block DNA repair in BRCA-mutated tumors.
- **Examples**:
  - *Olaparib*: Broad use in BRCA+ cancers (IC50: 0.09 nM).
  - *Talazoparib*: Most potent PARP1/2 inhibitor (IC50: 0.57 nM).

### 4. **BRAF/MEK Inhibitors**
- **Mechanism**: Target MAPK pathway in BRAF V600E mutations.
- **Examples**:
  - *Dabrafenib* + *Trametinib*: Combo for melanoma (IC50: 0.006 nM / 0.05 nM).

### 5. **Immune Checkpoint Inhibitors**
- **Mechanism**: Block PD-1/PD-L1/CTLA-4 to reactivate T-cells.
- **Examples**:
  - *Pembrolizumab*: PD-1 inhibitor for MSI-H/dMMR tumors (IC50: 0.15 nM).
  - *Ipilimumab*: CTLA-4 inhibitor (IC50: 0.22 nM).

### 6. **Antibody-Drug Conjugates (ADCs)**
- **Mechanism**: Targeted delivery of cytotoxic payloads.
- **Examples**:
  - *Trastuzumab deruxtecan*: HER2-targeted ADC (IC50: 0.04 nM).
  - *Sacituzumab govitecan*: TROP-2 ADC for TNBC (IC50: 0.3 nM).

### 7. **BCR-ABL Inhibitors**
- **Mechanism**: Target BCR-ABL fusion in CML.
- **Examples**:
  - *Imatinib*: First TKI (IC50: 0.58 nM).
  - *Ponatinib*: For T315I resistance (IC50: 0.08 nM).

### 8. **IDH Inhibitors**
- **Mechanism**: Block mutant IDH1/2 enzymes in AML.
- **Examples**:
  - *Ivosidenib*: IDH1 R132H inhibitor (IC50: 0.07 nM).

---

## Clinical Evidence Highlights
| Drug            | Trial Name       | Evidence Summary                          |
|-----------------|-----------------|------------------------------------------|
| Osimertinib     | FLAURA Phase III | Improved survival in EGFR T790M NSCLC.   |
| Olaparib        | OlympiAD        | Efficacy in BRCA-mutated breast cancer.  |
| Nivolumab       | CheckMate-067   | Durable responses in melanoma.           |
| Dabrafenib      | BREAK-3         | Improved PFS in BRAF V600E melanoma.     |

---

## Side Effects Overview
- **Common**: Fatigue, rash, diarrhea, nausea.
- **Severe**: 
  - *Cardiotoxicity* (Trastuzumab).
  - *Interstitial lung disease* (Trastuzumab deruxtecan).
  - *Immune-related toxicities* (PD-1 inhibitors).

---

## Approval Status
- **FDA-Approved**: 49/60 drugs (e.g., Pembrolizumab, Atezolizumab).
- **Investigational**: 11/60 drugs (e.g., Merestinib, Foretinib).

---

## References
- Clinical trials: NCT IDs, FDA labels, and peer-reviewed publications.
- **IC50 Values**: Lower values indicate higher potency.
- **Confidence Scores**: Reflect clinical validation (scale: 0â€“100).

---
*Last updated: July 2025*  
*Data source: Curated oncology drug database*